| 包装 | 价格(元) |
| 10mg | 电议 |
| 50mg | 电议 |
Cell lines | Multiple myeloma cell lines |
Preparation Method | Multiple myeloma cell lines were treated for 48 hours with vehicle or various concentrations of 4-Hydroxytamoxifen (1-10 μmol/L). Cell cycle analysis was done after propidium iodide staining of ethanol-permeabilized cells. |
Reaction Conditions | 1-10 μmol/L;for 48 hours |
Applications | G1-arrest and apoptosis induction of multiple myeloma cells after 4-Hydroxytamoxifen treatment. |
Animal models | iCM-Akt1/2, iCM-Gsk3β or iCM-p38 mice aged 3–4 month |
Preparation Method | For knockout induction, iCM-Akt1/2, iCM-Gsk3β or iCM-p38 mice aged 3–4 month received 4-Hydroxytamoxifen intraperitoneally (20 mg/kg) for either 5, 7, or 10 consecutive days, respectively, and hearts were excised two weeks after the end of the 4-Hydroxytamoxifen treatment for western blot analysis of protein depletion. In addition, immunohistological stainings were performed of hearts from iCM-Akt1/2KO or WT mice two weeks after 5 day 4-Hydroxytamoxifen treatment. |
Dosage form | 20 mg/kg; for either 5, 7, or 10 consecutive days |
Applications | Cardiomyocyte restricted gene deletion was initiated by intraperitoneal application of 20 mg/kg 4-Hydroxytamoxifen on 5, 7 or 10 consecutive days. Administration of 20 mg/kg 4-Hydroxytamoxifen for five consecutive days resulted in loss of both Akt1 and Akt2 in cardiomyocytes. |
| 产品描述 | 4-hydroxytamoxifen is a major metabolite of tamoxifen and selective estrogen receptor antagonist. It potentiated the protective effects of estradiol against the MA-induced nigrostriatal DA depletion.[1]4-Hydroxytamoxifen has the superoxide anion radical-scavenging activity, the antioxidative characteristics of 4-Hydroxytamoxifen can attenuate the MA-induced dopaminergic toxicity.[4] In vitro, 4-Hydroxytamoxifen decreased the transcriptional activity of ERRγ by more than 75%, with an EC50 value of 2 μM.[5]In MPNST cells were treated with 8-12 μM 4-Hydroxytamoxifen after 48 hours, there has a concentration-dependent increase in caspase 3-like enzymatic activity. 4-Hydroxytamoxifen also triggers autophagic death in MPNST cells.[2]In vitro study it indicated that 10 or 2 μM 4-hydroxytamoxifen abolished the generation of action potentials and repolarized the membrane potential in rat pancreatic beta-cells stimulated by 16 mM glucose. 4-hydroxytamoxifen impairs beta-cell electrical and secretory activity by inhibiting calcium and anion channel currents.[6] In vivo experiment it shown that αMHC-MerCreMer mice were treated 20 mg/kg 4-hydroxytamoxifen intraperitoneally for 5 consecutive days, neither cardiac function nor cardiac energetic status in αMHC-MerCreMer mice was disturbed. In addition, the injection of 40 mg/kg 4-hydroxytamoxifen also did not impair cardiac function.[3]In vivo efficacy test it demonstrated that treatment with 6 μg/0.1 mL/day subcutaneously of 4-Hydroxytamoxifen significantly mitigated MA-induced nigrostriatal DA and DOPAC depletions in both male and female mice.[4] References: |
m.cnreagent.com